Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944416 | 0.82 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13563924 | 0.78 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL443058 | 0.76 | CYP2C9 (0.39) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL25015250 | 0.73 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL14037264 | 0.72 | CYP2C19 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL18871348 | 0.72 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL2611129 | 0.70 | TSHR (0.39) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL24311782 | 0.69 | CYP2C9 (0.34) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL8472358 | 0.69 | CYP2C9 (0.39) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL9055690 | 0.69 | TAAR1 (0.41) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | CYP2C9 1507/4885TSHR 1799/4885CYP2C19 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.